Believer Meats

Believer began in 2018 as Future Meat Technologies, spun out of the Hebrew University of Jerusalem by biomedical engineering professor Yaakov Nahmias. Where much of the young cultivated-meat field chased beef and celebrity demos, Nahmias fixed on the least glamorous, most decisive variable: cost. The company's core claim was a fermentation-and-cell-culture process that could drive the price of cultured chicken toward parity with conventional poultry, and it published aggressive cost-per-pound targets that made it a favorite of investors betting the whole category on a manufacturing-economics breakthrough rather than a taste one. It built a pilot line in Rehovot, Israel, and framed itself less as a food brand than as a scale-up engineering problem.

Money followed the thesis. A $347 million round in December 2021 — one of the largest ever in cultivated meat at the time — drew in food-industry strategics including Tyson Foods and ADM alongside S2G Ventures and others, pushing lifetime funding past $387 million. In 2022 the company rebranded from Future Meat to Believer Meats, signaling a shift from lab credibility to consumer ambition. Its centerpiece was a production facility in Wilson, North Carolina, announced as one of the largest cultivated-meat plants in the world and designed to produce tens of thousands of pounds of cultured chicken a year. It was the physical embodiment of the cost-at-scale bet: prove the unit economics in a real factory, then flood the market.

In 2025 Believer collected the credentials most of its peers could only aspire to. The US FDA issued a 'No Questions' letter accepting the safety of its cultured chicken, and the USDA cleared the Wilson facility — the regulatory double-clearance that, in theory, opened the door to US commercial sales. But the path there had taken far longer than planned. The FDA review stretched more than a year past expectations; the war in Gaza pulled Israeli R&D staff into extended reserve duty, delaying trials; and the North Carolina build ran over, with projected costs climbing from roughly $138 million toward $154 million. Every month of delay was a month of burn against a category whose investor enthusiasm was rapidly cooling.

By late 2025 the company was out of runway and hunting for an eleventh-hour raise. Cultivated meat had fallen deeply out of favor — public comparables had cratered, several peers had shut or pivoted, and state-level bans on lab-grown meat had spooked backers. At a November town hall, staff were told a rescue financing was being pursued. It did not materialize. Compounding the crisis, contractor Gray Construction filed a roughly $35 million lawsuit alleging unpaid bills on the Wilson plant — which Believer itself later characterized as 'the straw that broke the camel's back.' A finished factory it could not afford to run became a liability rather than an asset.

Around December 1, 2025, Believer Meats ceased operations and laid off nearly its entire workforce, its global HR lead confirming the company had 'made the difficult decision to cease operations.' Subsequent bankruptcy filings revealed the company was nearly $225 million in debt; a US receiver moved to liquidate the North Carolina factory and its assets while an Israeli trustee ringfenced the underlying intellectual property. The collapse was the cleanest cautionary tale the cultivated-meat sector had produced: a company that had done everything the industry said was necessary — driven down cost claims, cleared the FDA, built and USDA-certified a flagship plant — and still could not raise the operating capital to turn any of it into a single commercial sale. Regulatory and engineering wins, Believer proved, are worth nothing without a financing market willing to fund the years of losses that scale requires.